CD274 and hepatocellular carcinoma: Sequential ICIs (anti-PD-1: sintilimab or camrelizumab, ati-PD-L1: atezolizumab) plus bevacizumab plus bevacizumab therapy after radiotherapy for PVTT in patients with HCC was safe and feasible, potentially prolonging PFS (125).